
Privacy notice | Accessibility statement | Terms and conditions | Login | Contact |
UK data driving real-world evidence
Bibliography
Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 4 March 2021) and papers are listed below and in the PDF below.
If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.
Download:
(PDF, 3MB, 220 pages)This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website.
“Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics”, N Engl J Med, vol. 349, pp. 1628-35, 2003.
, “Adverse events associated with prolonged antibiotic use”, Pharmacoepidemiol Drug Saf, vol. 17, pp. 523-32, 2008.
, “Antidiabetic action of bezafibrate in a large observational database”, Diabetes Care, vol. 32, pp. 547-51, 2009.
, “Chronic proton pump inhibitor therapy and the risk of colorectal cancer”, Gastroenterology, vol. 133, pp. 748-54, 2007.
, “Chronic statin therapy and the risk of colorectal cancer”, Pharmacoepidemiol Drug Saf, vol. 17, pp. 869-76, 2008.
, “Comparative cardiac safety of low-dose thioridazine and low-dose haloperidol”, Br J Clin Pharmacol, vol. 58, pp. 81-7, 2004.
, “Concordance of hospitalizations between Clinical Practice Research Datalink and linked Hospital Episode Statistics among patients treated with oral antidiabetic therapies”, Pharmacoepidemiol Drug Saf, 2019.
“Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs”, BMC Pharmacol Toxicol, vol. 16, p. 8, 2015.
“Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients”, Gastroenterology, vol. 127, pp. 1044-50, 2004.
, “Observed association between antidepressant use and pneumonia risk was confounded by comorbidity measures”, J Clin Epidemiol, vol. 60, pp. 911-8, 2007.
, “Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes”, BMJ Open Diabetes Res Care, vol. 5, p. e000400, 2017.
, “Proton pump inhibitors and traditional nonsteroidal anti-inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury”, Pharmacoepidemiol Drug Saf, vol. 21, pp. 1155-72, 2012.
, “Represcription of penicillin after allergic-like events”, J Allergy Clin Immunol, vol. 113, pp. 764-70, 2004.
, “Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies”, Pharmacoepidemiol Drug Saf, vol. 21, pp. 1202-15, 2012.
, “Is there cross-reactivity between penicillins and cephalosporins?”, Am J Med, vol. 119, pp. 354.e11-9, 2006.
, “Type 2 diabetes mellitus and the risk of colorectal cancer”, Clin Gastroenterol Hepatol, vol. 3, pp. 587-94, 2005.
, “Use of demographic and pharmacy data to identify patients included within both the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN)”, Pharmacoepidemiol Drug Saf, vol. 24, pp. 999-1003, 2015.